Anti-human intercellular adhesion molecule-1 antibody, antibody pair and application thereof

By developing high affinity and specific rabbit-derived antibodies, the stability and sensitivity problems of ICAM-1 detection in the prior art are solved, and high-precision detection of human cell adhesion molecule-1 is achieved, providing an efficient detection Solution.

CN119039439AActive Publication Date: 2024-11-29WUHAN AIBO TAIKE BIOTECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410839172.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-26
Publication Date
2024-11-29
Estimated Expiration
2044-06-26

AI Technical Summary

Technical Problem

In the prior art, the murine monoclonal antibodies used to detect intercellular adhesion molecule-1 (ICAM-1) have low affinity and specificity, and the preparation process is complex, resulting in poor detection stability and low sensitivity.

Method used

A rabbit-derived antibody was developed, and the antibody gene sequence was directly expanded from immunized rabbit B lymphocytes through B cell marking and sorting technology and recombinantly expressed, to prepare human intercellular adhesion molecules with high affinity and specificity- 1 Antibody and antibody pairs are used to build a dual-anti-sandwich enzyme-linked immunoassay detection system.

Benefits of technology

It realizes high-precision detection of human ICAM-1, with high affinity, strong specificity, strong anti-interference ability, high detection sensitivity and good stability, significantly improving the accuracy and reliability of the detection results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039439A_ABST
    Figure CN119039439A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of antibodies, and particularly relates to an anti-human intercellular adhesion molecule-1 antibody, an antibody pair and application thereof. The antibody is a first antibody or a second antibody, amino acid sequences of CDR1-3 on a light chain variable region of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of CDR1-3 on a heavy chain variable region of the first antibody are respectively shown as SEQ ID NO.8-10; amino acid sequences of CDR1-3 on a light chain variable region of the second antibody are respectively shown as SEQ ID NO.13-15, and amino acid sequences of CDR1-3 on a heavy chain variable region of the second antibody are respectively shown as SEQ ID NO.18-20. The invention provides an antibody and an antibody pair capable of specifically recognizing human ICAM-1, which are used for developing an immunodetection system to detect the human ICAM-1 and have the advantages of high affinity and specificity, strong anti-interference capability, high detection sensitivity, good stability and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antibody technology, and in particular to anti-human intercellular adhesion molecule-1 antibodies, antibody pairs and applications thereof. Background Art

[0002] Intercellular Cell Adhesion Molecule-1 (ICAM-1), also known as CD54, has a relative molecular weight of 70-110kD. It is a single-chain glycoprotein and a member of the immunoglobulin superfamily (IGSF) of adhesion molecules. It is an important adhesion molecule that mediates cell adhesion reactions. It participates in important physiological processes such as cell signal transduction and activation, immune response, and inflammatory response. ICAM-1 is constitutively expressed at a low level in various cells, such as endothelial cells, immune cells, and some epithelial cells. Its expression is upregulated under the stimulation of various inflammatory factors such as TNF-α, IFN-α, IFN-γ, IL-1β, and IL-6, but there is a certain degree of specificity between different types of cells. The expression of ICAM-1 in endothelial cells is induced by TNF-α, the expression of ICAM-1 in intestinal epithelial cells is induced by IFN-α, and the expression of ICAM-1 in macrophages is mainly induced by IFN-γ and polysaccharides. The expression of ICAM-1 is also regulated by microRNA activity. ICAM-1 is mainly involved in leukocyte transport and immune cell recruitment. It mediates vascular adhesion and paracellular migration of leukocytes expressing activated LFA-1 (CD11a / CD18) and Mac-1 (CD11b / CD18), plays an important role in immune surveillance, inflammatory response and immune response, and also binds to several non-integrin ligands, including CD43 / sialic acid protein, fibrinogen, hyaluronic acid, rhinovirus and Plasmodium falciparum infected red blood cells, and participates in inflammatory allergic reactions and transplant rejection. ICAM-1 is also involved in immune cell interactions, such as T cell activation, antigen presentation and the formation of immune synapses.

[0003] Abnormal expression of ICAM-1 is associated with a variety of pathological processes, especially those associated with inflammatory responses and immune-mediated diseases. During inflammation, upregulation of ICAM-1 in endothelial cells promotes leukocyte adhesion and tissue infiltration, and is associated with the pathogenesis of diseases such as atherosclerosis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. In addition, studies have shown that ICAM-1 can promote the migration of cancer cells; ICAM-1 is upregulated in triple-negative breast cancer (TNBC) and colorectal cancer (CRC), and is closely related to tumor invasion, metastasis, and poor prognosis. Targeting ICAM-1 can reduce the metastasis and angiogenesis of CRC. Therefore, ICAM-1 is expected to become a diagnostic and therapeutic target for TNBC and CRC, and the detection of this indicator is of great clinical significance.

[0004] At present, the level of ICAM-1 is mostly measured by immunological methods such as enzyme-linked immunosorbent assay, immunoturbidimetry, immunoprecipitation, and immunofluorescence. Different methods require specific monoclonal antibodies against ICAM-1. Traditional clinical diagnosis uses mouse monoclonal antibodies, which generally have lower affinity and specificity than rabbit monoclonal antibodies. In addition, the mouse monoclonal antibodies used rely on the traditional hybridoma method for development and production. The preparation process is more complicated than that of recombinant monoclonal antibodies, and there are also large batch differences. Therefore, immunoassay reagents developed based on mouse monoclonal antibodies face challenges such as poor stability and low sensitivity. Summary of the invention

[0005] In view of the problems existing in the prior art, the present invention provides an antibody and an antibody pair that can specifically recognize human ICAM-1, which are used to develop an immune detection system to detect ICAM-1 and have the advantages of high affinity and specificity, strong anti-interference ability, high detection sensitivity and good stability, etc., and provide an effective solution for the high-precision detection of trace levels of human ICAM-1 in biological samples. Therefore, the present invention also provides the use of the aforementioned antibodies and antibody pairs in the preparation of human ICAM-1 detection reagents or kits, and provides detection reagents or kits containing the aforementioned antibodies and antibody pairs. The present invention is achieved through the following technical solutions:

[0006] The first aspect of the present invention provides an anti-human intercellular adhesion molecule-1 antibody, selected from a first antibody or a second antibody, wherein: the amino acid sequences of CDR1-3 on the light chain variable region of the first antibody are respectively shown as SEQ ID NOs.3-5, and the amino acid sequences of CDR1-3 on the heavy chain variable region are respectively shown as SEQ ID NOs.8-10; the amino acid sequences of CDR1-3 on the light chain variable region of the second antibody are respectively shown as SEQ ID NOs.13-15, and the amino acid sequences of CDR1-3 on the heavy chain variable region are respectively shown as SEQ ID NOs.18-20.

[0007] Furthermore, the amino acid sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.7; the amino acid sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.17.

[0008] Furthermore, the amino acid sequence of the light chain of the first antibody is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.6; the amino acid sequence of the light chain of the second antibody is shown as SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.16.

[0009] Furthermore, the first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; the antigen-binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.

[0010] The second aspect of the present invention provides a nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody or the second antibody as described above.

[0011] Furthermore, the nucleotide sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.22, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.24; the nucleotide sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.26, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.28.

[0012] Furthermore, the nucleotide sequence of the light chain of the first antibody is shown as SEQ ID NO.21, and the nucleotide sequence of the heavy chain is shown as SEQ ID NO.23; the nucleotide sequence of the light chain of the second antibody is shown as SEQ ID NO.25, and the nucleotide sequence of the heavy chain is shown as SEQ ID NO.27.

[0013] The third aspect of the present invention provides an anti-human intercellular adhesion molecule-1 antibody pair, which consists of the first antibody and the second antibody as described above.

[0014] The fourth aspect of the present invention provides the use of the anti-human intercellular adhesion molecule-1 antibody or antibody pair as described above in the preparation of a human intercellular adhesion molecule-1 detection reagent or kit.

[0015] The fifth aspect of the present invention provides a human intercellular adhesion molecule-1 detection reagent or kit, which is a double antibody sandwich enzyme-linked immunosorbent assay reagent or kit, comprising a first antibody and a second antibody, wherein the first antibody serves as a capture antibody, and the second antibody modified with a detection marker serves as a detection antibody.

[0016] Compared with the prior art, the advantages and positive effects of the present invention are:

[0017] 1. The antibody provided by the present invention can specifically recognize human ICAM-1 protein, has the advantages of good binding activity, high affinity and strong specificity, and has low cross-reactivity with similar proteins, providing a reliable antibody raw material for immunodetection of ICAM-1 protein, and has broad market prospects and good economic benefits in the fields of clinical diagnosis and scientific research.

[0018] 2. The rabbit monoclonal antibody against human intercellular adhesion molecule-1 of the present invention binds to different antigenic epitopes on the surface of human intercellular adhesion molecule-1. The double antibody sandwich enzyme-linked immunosorbent assay system developed using the antibody has the advantages of high specificity, strong anti-interference ability, high detection sensitivity and good stability, and provides an effective solution for the high-precision detection of extremely trace levels of human ICAM-1 protein in biological samples.

[0019] 3. The present invention is based on B cell labeling and sorting technology, directly amplifies the antibody gene sequence from the immunized rabbit B lymphocytes and performs recombinant expression. The antibody preparation method is simple and can achieve large-scale preparation of antibodies. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments.

[0021] Figure 1 The vector map used to construct the rabbit monoclonal antibody expression vector in Example 1 of the present invention, from left to right, are the pBR322 vector maps carrying the light chain constant region and the heavy chain constant region;

[0022] Figure 2 This is an affinity curve diagram of the binding of monoclonal antibody 2B10 of Example 2 of the present invention to human ICAM-1 protein;

[0023] Figure 3 This is an affinity curve diagram of the binding of monoclonal antibody 1F10 to human ICAM-1 protein in Example 2 of the present invention;

[0024] Figure 4 This is a curve diagram showing that the monoclonal antibodies 2B10 and 1F10 of Example 2 of the present invention recognize the epitope of human ICAM-1;

[0025] Figure 5 The standard curve for detecting human ICAM-1 protein using a double antibody sandwich ELISA system based on monoclonal antibodies 2B10 and 1F10 established in Example 3 of the present invention;

[0026] Figure 6 This is a graph showing the specificity determination results of the double antibody sandwich ELISA system established based on rabbit monoclonal antibodies 2B10 and 1F10 in Example 4 of the present invention;

[0027] Figure 7 This is a graph showing the results of thermal stability determination of a double antibody sandwich ELISA system established based on rabbit monoclonal antibodies 2B10 and 1F10 in Example 5 of the present invention. DETAILED DESCRIPTION

[0028] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0029] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.

[0030] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values ​​used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.

[0031] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.

[0032] The meaning of the terms "including", "comprising", "containing", "having" and the like is non-restrictive, that is, other steps and other ingredients that do not affect the results can be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" is regarded as including the following situations: (i) A, (ii) B and (iii) A and B. The terms "first", "second", etc. are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that such usage can be interchangeable under appropriate circumstances.

[0033] The terms "monoclonal antibody", "antibody" and "monoclonal antibody" and similar words have the same meaning and can be used interchangeably. Unless otherwise specified, in the present invention, they all refer to rabbit antibodies that specifically bind to human intercellular adhesion molecule-1 (ICAM-1). The modifier "rabbit" indicates that the complementary determining region of the antibody is derived from a rabbit immunoglobulin sequence. The terms "human intercellular adhesion molecule-1", "Human ICAM-1" and similar words have the same meaning and can be used interchangeably.

[0034] An antibody is an immunoglobulin molecule that is able to specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen-binding activity. An antibody fragment can be one or more parts or fragments of a full-length antibody that retain the ability of the antibody to specifically bind to a target antigen.

[0035] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, which determines the specificity of the antibody and is the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0036] CDRs and FRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, the Kabat numbering system is used to define.

[0037] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.

[0038] A full-length antibody is the most complete antibody molecular structure and has a typical Y-shaped molecular structure. Therefore, in the context of the present invention, "full-length antibody", "complete antibody" and "Y-shaped antibody" have the same meaning and can be used interchangeably.

[0039] Antibody fragments are one or more parts or fragments of a full-length antibody, which substantially retain the same biological function or activity as the full-length form. Specifically, antibody fragments at least include the same CDR region as the full-length antibody, and more preferably have the same variable region, thereby retaining complete antigen recognition and binding sites, and can bind to the same antigen as the full-length antibody, especially to the same epitope. In typical examples, antibody fragments include: Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv, sc(Fv)2, and these antibody fragments can be obtained by conventional techniques in the art.

[0040] (i) Fab: Antigen-binding fragment (Fab) is a monovalent fragment consisting of a complete light chain (variable region and constant region) and a part of the heavy chain (variable region and the first constant region). By proteolytic cleavage of the full-length antibody, fragments such as Fab, F(ab')2, and Fab' can be obtained. For example, under the action of papain, IgG can be degraded into two Fab fragments and one Fc fragment; under the action of pepsin, IgG can be degraded into one F(ab')2 fragment and one pFc' fragment. The F(ab')2 fragment is further reduced to form two Fab' fragments. Since Fab has an antigen-binding region and a part of the constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration as scFv, but also has a more stable structure.

[0041] (ii) F(ab)2: A bivalent fragment consisting of two Fabs linked by a disulfide bridge at the hinge region.

[0042] (iii) Fv: The variable fragment (Fv) is located at the N-terminus of the antibody Fab fragment, contains only the variable region, and is composed of the variable regions of a light chain and a heavy chain. It is a dimer of VH and VL non-covalently bound (VH-VL dimer). The three CDRs of each variable region interact with each other to form an antigen binding site on the surface of the VH-VL dimer, which has the ability to recognize and bind to antigens, although the affinity is lower than that of the intact antibody.

[0043] (iv) (Fv)2: consists of two Fv fragments covalently linked together.

[0044] (v) scFv: Single-chain variable fragment (scFv) is an Fv fragment composed of a single polypeptide chain, which is composed of a heavy chain variable region (VH) and a light chain variable region (VL) connected by a flexible linker (generally composed of 10-25 amino acids), which retains the binding specificity of the original antibody to the antigen. The linker in the present invention is not particularly limited as long as it does not hinder the expression of the antibody variable regions connected to its two ends. Compared with full-length antibodies, scFv has the characteristics of small molecular weight, so it has higher penetration and lower immune side effects.

[0045] (vi) The sc(Fv)2 fragment is composed of two heavy chain variable regions and two light chain variable regions connected via a linker or the like.

[0046] The terms "monoclonal antibody" or "single antibody" and the like are used interchangeably and refer to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for a small amount of mutations and / or post-translational modifications (e.g., isomerization, amidation) that may occur naturally. "Monoclonal antibodies" are highly specific and exhibit a single binding specificity and affinity for the same or substantially identical epitopes on an antigen. The modifier "monoclonal" indicates that the antibody is obtained from a substantially homogeneous antibody population and should not be construed as limiting the source or preparation method of the antibody. The antibody can be prepared by a variety of methods, including but not limited to hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.

[0047] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.

[0048] In order to make the above-mentioned objects and advantages of the present invention more obvious and understandable, the specific implementation methods of the present invention are described in detail below.

[0049] An embodiment of the present invention provides an anti-human intercellular adhesion molecule-1 antibody, selected from a first antibody or a second antibody, wherein the first antibody and the second antibody both include a light chain variable region and a heavy chain variable region, and the light chain variable region and the heavy chain variable region both include three complementary determining regions (CDRs), respectively named CDR1, CDR2 and CDR3; wherein:

[0050] The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the first antibody are shown in SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively;

[0051] The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the second antibody are shown in SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown in SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, respectively.

[0052] Based on B cell labeling and sorting technology, the present invention directly enriches and separates B lymphocytes that can recognize human intercellular adhesion molecule-1 protein from the spleen of immunized rabbits, greatly improving the efficiency of antigen-specific B lymphocyte screening. Afterwards, the specific antibodies in B lymphocytes are amplified and recombinantly expressed through PCR, eliminating the cumbersome steps of multiple subcloning in hybridoma technology, and realizing large-scale preparation of antibodies.

[0053] The antibody containing the above CDR sequence prepared by the present invention has high affinity, good specificity and excellent anti-interference ability for human intercellular adhesion molecule-1 (ICAM-1), can specifically bind to human ICAM-1 protein, and has low cross-reactivity with similar proteins such as human VCAM-1. It is used for immunodetection of ICAM-1 protein in biological samples, which is conducive to significantly improving the accuracy, sensitivity, stability and reliability of detection results, and reducing false negative or false positive results. Moreover, the two antibodies of the present invention recognize different antigenic epitopes on the surface of human ICAM-1 protein, and a double antibody sandwich enzyme-linked immunosorbent (ELISA) detection system is constructed with the first antibody as the capture antibody and the second antibody as the detection antibody. The detection limit of human ICAM-1 is as low as 5.54pg / mL, which provides an effective solution for the high-precision detection of extremely trace levels of human ICAM-1 protein in biological samples, and has broad market prospects and good economic benefits in the fields of clinical diagnosis and scientific research.

[0054] Optionally, the light chain variable region and the heavy chain variable region each include 4 framework regions (FRs), and the 4 FRs and 3 CDRs are arranged alternately in sequence to form a variable region. The amino acid sequence of the light chain variable region (VL) of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.7. The amino acid sequence of the light chain variable region (VL) of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.17.

[0055] Optionally, the first antibody and the second antibody further include a light chain constant region (CL) and a heavy chain constant region (CH), and each antibody CL and VL constitute a light chain (FL), and CH and VH constitute a heavy chain (FH). The constant region of an antibody can usually be obtained through public inquiries, such as: searching for rabbit IgG gamma C reign to obtain CH through the IMGT online database (www.imgt.org), and searching for rabbit IgG Kappa C reign to obtain CL. Specifically, the amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6. The amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.16. Among them, the light chain constant region of the first antibody and the second antibody is a κ chain, and the heavy chain constant region is an IgG1 type.

[0056] Optionally, the first antibody and / or the second antibody is a full-length antibody (having a typical Y-shaped molecular structure) or an antigen binding region of the full-length antibody; the antigen binding region refers to a polypeptide that substantially maintains the same biological function or activity as the full-length form of a rabbit monoclonal antibody. Specifically, the antigen binding region includes the CDR region as described above, and more preferably has the variable region as described above, thereby retaining a complete antigen recognition and binding site, and can bind to the same antigen as the full-length antibody, especially to the same epitope. Optionally, the antigen binding region is selected from at least one of Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv and sc(Fv)2. These antigen binding regions can be obtained by conventional techniques in the art.

[0057] Yet another embodiment of the present invention provides a nucleic acid molecule, a recombinant vector or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody and / or the second antibody as described above.

[0058] Nucleic acid molecules can be in the form of DNA (such as cDNA or genomic DNA or synthetic DNA) or RNA (such as mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can also be a coding strand or a non-coding strand.

[0059] The sequence of the nucleic acid molecule can be derived from the antibody AA sequence by conventional means such as codon coding rules. The full-length sequence of the nucleic acid molecule or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. The obtained nucleic acid molecule is inserted into an expression vector, then introduced into a host cell, and cultured under specific conditions to express the antibody.

[0060] Illustratively, the nucleotide sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.22, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.24; the nucleotide sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.26, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.28.

[0061] Illustratively, the nucleotide sequence of the light chain of the first antibody is shown as SEQ ID NO.21, and the nucleotide sequence of the heavy chain is shown as SEQ ID NO.23; the nucleotide sequence of the light chain of the second antibody is shown as SEQ ID NO.25, and the nucleotide sequence of the heavy chain is shown as SEQ ID NO.27.

[0062] The original vector for constructing the recombinant vector is various vectors conventional in the art, as long as it can hold the nucleic acid molecule. Typical vectors include plasmids (e.g., pBR322, pUC series, pET series pGEX series), viral vectors, bacteriophages (e.g., λgt4λB, λ-Charon, λΔz1, and M13), cosmids, and minichromosomes. The vector can be a cloning vector (i.e., used to transfer the nucleic acid molecule to a host and multiply in a host cell) or an expression vector (i.e., containing necessary genetic elements to allow the nucleic acid molecule inserted into the vector to be expressed in a host cell). The nucleic acid molecule of the present invention can be inserted into a suitable vector to form a cloning vector or an expression vector carrying the nucleic acid molecule.

[0063] The nucleic acid molecules encoding the antibodies FL and FH of the present invention can be inserted into two vectors, respectively, which can be introduced into the same or different host cells. When the heavy chain and the light chain are expressed in different host cells, each chain can be separated from the host cell expressing it, and the separated heavy chain and light chain are mixed and incubated under suitable conditions to form antibodies. In other embodiments, the nucleic acid molecules of antibodies FL and FH can also be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding the heavy chain and the light chain can be operably connected to different promoters, or the nucleic acid sequence encoding the heavy chain and the light chain can be operably connected to a single promoter, so that both the heavy chain and the light chain can be expressed by the same promoter. The choice of expression vector / promoter depends on the type of host cell used to produce the antibody.

[0064] The recombinant vector is transfected or transformed into the host cell using conventional techniques. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA are harvested after the exponential growth period and treated with CaCl2 or MgCl2; they can also be transfected by microinjection, electroporation or liposome packaging. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation, microinjection, electroporation, liposome packaging or particle bombardment to achieve gene introduction.

[0065] The host cell can be a prokaryotic or eukaryotic cell. Examples of prokaryotic host cells that can be used in the present invention include Escherichia coli (e.g., DH5α, JM109, BL21, W3110), Bacillus (e.g., Bacillus subtilis, Bacillus thuringiensis) and Enterobacteriaceae strains (e.g., Salmonella typhimurium, Serratia marcescens) and Pseudomonas. Examples of eukaryotic host cells that can be used for transformation include yeast, insect cells, and animal cells, such as Drosophila S2 or Sf9 cells, mammalian CHO, CHODG44, CHO-S, COS-7, 293 series cells, HepG2, Huh7, 3T3, RIN, MDCK, HEK293 cell lines, etc., but are not limited thereto. After obtaining a host cell transfected or transformed with a recombinant vector as described above, the antibody can be expressed by culturing under suitable conditions, and then separated to obtain a purified antibody.

[0066] In a preferred embodiment, the recombinant vector is a mammalian expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).

[0067] Another embodiment of the present invention provides an anti-human intercellular adhesion molecule-1 antibody pair, which is composed of the first antibody and the second antibody as described above.

[0068] The first antibody and the second antibody of the present invention bind to different antigenic epitopes of human ICAM-1 and can be used to develop a double antibody sandwich enzyme-linked immunosorbent assay system, which has the advantages of high specificity, wide linear range, high detection sensitivity and strong anti-interference ability.

[0069] Another embodiment of the present invention provides the use of the anti-human intercellular adhesion molecule-1 antibody or antibody pair described above in the preparation of a human intercellular adhesion molecule-1 detection reagent or kit.

[0070] The advantages of using the anti-human ICAM-1 antibody or antibody pair in preparing a human ICAM-1 detection reagent or kit are the same as those of the anti-human ICAM-1 antibody or antibody pair described above over the prior art, and will not be elaborated herein.

[0071] Based on the same inventive concept as above, an embodiment of the present invention further provides a human intercellular adhesion molecule-1 detection reagent or kit, wherein the detection reagent or kit comprises the first antibody and / or the second antibody as described above.

[0072] It should be emphasized that the first antibody and the second antibody can be used separately, together, or in pairs. When detecting, if used separately or together, the first antibody and / or the second antibody is used as a primary antibody or a capture antibody, the sample to be tested is contacted with the first antibody and / or the second antibody, and then the antibody is detected. In some embodiments, the first antibody and / or the second antibody can be coupled to a detectable label, and the qualitative or quantitative detection of ICAM-1 is achieved by analyzing the change in the identifiable signal generated by the detectable label. In other embodiments, the anti-human ICAM-1 antibody (as a primary antibody or a capture antibody) is not labeled, and the detectable label is coupled to a secondary antibody (as a detection antibody) or other molecules that can bind to the primary antibody. For example, if the anti-human ICAM-1 antibody is a rabbit IgG antibody, the secondary antibody can be an anti-rabbit IgG antibody, thereby generating a change in the identifiable signal by coupling the detectable labeled secondary antibody. If used in pairs, one of the first antibody and the second antibody is used as a primary antibody or a capture antibody, and the other is used as a secondary antibody or a detection antibody.

[0073] The above-mentioned detection method adopts common immunological methods, including but not limited to: enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), immunohistochemistry (IHC), immunofluorescence (IF), immunoblotting (WB), flow cytometry (FC), etc. The detection object includes recombinantly expressed ICAM-1 protein, cell-secreted ICAM-1 protein or ICAM-1 protein in human serum. The detection samples include but are not limited to serum, plasma, urine, and cell culture fluid.

[0074] Preferably, the detection reagent or kit is a double antibody sandwich enzyme-linked immunosorbent assay reagent or kit, comprising a first antibody and a second antibody, wherein the first antibody serves as a capture antibody (or primary antibody), and the second antibody modified with a detection marker serves as a detection antibody (or secondary antibody).

[0075] The above-mentioned detection labels for generating identifiable signal changes include, but are not limited to: biotin, fluorescent dyes (such as umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride), fluorescent proteins (such as allophycocyanin, phycoerythrin, PerCP and phycocyanin), enzymes (such as alkaline phosphatase, acid phosphatase, β-galactosidase, glucose oxidase, horseradish peroxidase, acetylcholinesterase, avidin), colloidal gold, colored magnetic beads, latex particles, radionuclides, detection antibodies or combinations thereof.

[0076] In a preferred embodiment, the detection label is biotin.

[0077] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.

[0078] Example 1 Preparation of human ICAM-1 rabbit monoclonal antibody

[0079] Human intercellular adhesion molecule-1 (ICAM-1) (from ABclonal, catalog number RP00272) was used as an antigen to immunize New Zealand white rabbits. Antigen-specific B lymphocytes were isolated from the spleen cells after immunization and cultured. The genes of the heavy chain variable region (VH) and light chain variable region (VL) corresponding to the antibody were extracted by primers, constructed into expression vectors containing the heavy chain constant region and the light chain constant region, and transfected into host cells. The host cells were cultured to obtain the supernatant containing rabbit monoclonal antibodies, and the candidate antibodies were purified. After that, the antibodies were screened by affinity testing and antigen epitope identification, and the antibody strains 2B10 and 1F10 were obtained. The selected antibodies were sequenced, and the sequencing work was completed by Jinkairui Biotechnology Co., Ltd. The amino acid (AA) and nucleotide (DNA) sequences of the antibodies are shown in Tables 1-2, respectively. For convenience of description, the light chain complementary determining regions CDR1, CDR2 and CDR3 are represented by LCDR1, LCDR2 and LCDR3, respectively, and the heavy chain complementary determining regions CDR1, CDR2 and CDR3 are represented by HCDR1, HCDR2 and HCDR3, respectively.

[0080] Table 1 Sequence information of rabbit monoclonal antibody 2B10 in this example

[0081]

[0082]

[0083] Table 2 Sequence information of rabbit monoclonal antibody 1F10 in this example

[0084]

[0085] The preparation method of rabbit monoclonal antibodies 2B10 and 1F10 specifically comprises the following steps:

[0086] 1. Animal immunization: Each rabbit was immunized with 200 μg of antigen (from ABclonal, catalog number RP00272). Before the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant to prepare an emulsifier, which was injected subcutaneously at multiple points on the rabbit's abdomen and back; after the first immunization, 100 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant to prepare an emulsifier every 3 weeks, which was injected subcutaneously at multiple points on the rabbit's abdomen and back, and booster immunization was performed twice; after three immunizations, rabbit serum samples were collected, and the titer against human ICAM-1 was determined by ELISA method. Rabbits with high serum titers were selected and booster immunized once with 200 μg of the immunogen at multiple points subcutaneously. Three days later, the animals were sacrificed and the spleen was taken.

[0087] 2. Isolate spleen cells: Take out a culture dish in a safety cabinet under aseptic operation, add 30-40mL of basal culture medium (RPMI Medium 1640basic+1% Pen Strep; RPMI 1640 purchased from Gibco, item number C11875500BT; PenStrep purchased from Gibco, item number 15140-163), put a cell sieve, take out the spleen and put it in the cell sieve, cut off the excess connective tissue and fat on the rabbit spleen tissue, cut the spleen tissue into pieces and put it into the cell sieve for grinding, take a clean grinding rod, and use the end of the pressing part to crush the tissue. The cells in the grinding membrane will slowly free themselves, and after passing through the cell sieve, they will be suspended in the culture dish solution; wash the cell sieve with 10mL of basal culture medium, and collect the basal culture medium outside the cell sieve. Centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 13mL of RBC lysis solution at room temperature (purchased from BioGems), gently blow away the cell clusters with a pipette and then time for 1min to lyse the red blood cells, add 37mL of basal culture medium and mix well to terminate the red blood cell lysis, centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 40mL of basal culture medium placed at room temperature, gently blow away the cell clusters with a pipette, resuspend the cells, complete the first wash, centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 20mL of basal culture medium placed at room temperature, gently blow away the cell clusters with a pipette, and resuspend the cells; filter the resuspended cells again through a cell sieve to remove the clumping cells, and then count the cells.

[0088] 3. Isolate B lymphocytes from the spleen and sort B lymphocytes: Use conventional methods to isolate B lymphocytes from the spleen. For related methods, please refer to the patent "Method for efficiently separating single antigen-specific B lymphocytes from spleen cells (publication number: CN110016462A, publication date: 2019-07-16)" and the patent "A B lymphocyte in vitro culture system and application (publication number: CN111518765A, publication date: 2020-08-11)".

[0089] 4. Cloning of the gene encoding rabbit monoclonal antibody: The cultured B lymphocyte supernatant was used to identify positive clones by ELISA coated with ICAM-1 antigen to obtain antigen-specific B lymphocytes. The positive clone cells were collected and lysed and then analyzed by Quick-RNA TMRNA was extracted according to the instructions of the Micro Prep kit (purchased from ZYMO, catalog number R1051) and reverse transcribed into cDNA. Using the aforementioned cDNA as a template, the naturally paired rabbit monoclonal antibody light chain variable region (VL) and heavy chain variable region (VH) were amplified from the cDNA of the corresponding positive clone by PCR and sequenced. The sequencing work was completed by Jin Kairui Biotechnology Co., Ltd. The PCR reaction system included: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2×Gloria HiFi (from ABclonal, catalog number RK20717) and 6.5 μL H2O; the PCR amplification program included: 98℃ pre-denaturation for 30 s, followed by 40 cycles of 98℃ for 10 s, 64℃ for 30 s, and 72℃ for 30 s, and finally kept at 72℃ for 5 min. The resulting reaction solution was stored at 4℃. The primer sequences (5'-3') for amplifying VL and VH genes are shown in Table 3, where F and R represent forward primers and reverse primers, respectively.

[0090] Table 3 Primer sequence information for amplifying rabbit monoclonal antibodies in this example

[0091]

[0092]

[0093] 5. Production and purification of rabbit monoclonal antibodies: The mammalian expression vector pBR322 carrying the light chain constant region (CL) and heavy chain constant region (CH) genes was linearized with XbaI and NheI restriction enzymes respectively. The VL and VH genes containing the signal peptides amplified by the above PCR were purified and then constructed into the above expression vectors by homologous recombination to obtain light chain gene and heavy chain gene expression vectors. The expression vectors were successfully constructed and verified by sequencing. The expression map of the vector used is shown in Figure 1 , pBR322 origin and f1 origin are replication promoters, Ampcillin is a resistance gene, CMV promoter is a transcription promoter, SV40 PAterminator is a tailing signal, Light chain constant is the nucleic acid sequence of the light chain constant region (left), Heavy chain constant is the nucleic acid sequence of the heavy chain constant region (right). CL and CH genes were obtained by searching the IMGT online database (www.imgt.org) to obtain CH from rabbit IgG gamma C reign, and CL from rabbit IgG Kappa C reign.

[0094] The signal peptide of this embodiment can adopt the antibody expression signal peptide sequence commonly used in the art, such as the patent "Rabbit monoclonal antibody against human interferon α2 and its application (publication number: CN116063487A, publication date: 2023-05-05)" and the patent "High-affinity Human IL-5 rabbit monoclonal antibody and its application (publication number: CN115819578A, publication date: 2023-03-21)" The light chain variable region upstream has a signal peptide "MDTRAPTQLLGLLLLWLPGATF" or "MDTRAPTQLLGLLLLWLPGARC", and the heavy chain variable region upstream has a signal peptide "METGLRWLLLVAVLKGVQC".

[0095] The expression vectors containing the light chain gene and the heavy chain gene verified by sequencing were transfected into 293F cells together. After transfection, the cells were cultured for 72-96 hours to obtain the culture supernatant containing the recombinant rabbit monoclonal antibody that recognizes human ICAM-1. Protein A affinity gel resin (purchased from Tiandi Renhe, catalog number SA023100) was used to purify the target antibody from the culture supernatant. The purified antibody was aliquoted and stored at -20°C for later use.

[0096] Example 2 Performance Test of Rabbit Monoclonal Antibodies 2B10 and 1F10

[0097] 1) Affinity test: The above-obtained antibodies 2B10 and 1F10 were subjected to affinity identification using the Gator Biomolecular Interaction Analyzer (Gator Prime device) from Probe Life, and the probe used was ProteinAProbe. The specific method is as follows: 1) Pre-wet: Before use, the probe is shaken and wetted in the matching buffer at 1000rpm for 300s; 2) Baseline1: The probe is placed in the buffer for starting point calibration to ensure that the probe is initially in a stable state, and is treated at 1000rpm for 60s; 3) Loading: The antibody to be tested 2B10 / 1F10 is immobilized on the probe, and the immobilization concentrations are 2.49μg / mL and 5.76μg / mL, respectively, and it is treated at 1000rpm for 35s; 4) Baseline2: The probe with immobilized antigen is placed in the buffer for shaking and washing, and is treated at 1000rpm for 60s; 5) Association: The probe with immobilized antibody is placed in 75nM and 150nM antigen diluents, respectively, and is treated at 1000rpm for 240s to test the affinity of the antibody for binding to the antigen under different molar concentration conditions; 6) Dissociation: When the antigen-antibody binding reaches saturation, the probe is transferred to the dissociation system to complete the dissociation process, and is treated at 1000rpm for 240s. The affinity curves of antibodies 2B10 and 1F10 binding to human ICAM-1 are shown in Figure 2-3 , where the ordinate represents the change in the thickness of the conjugate after the probe binds to the antibody and protein, the abscissa represents the binding time, the dark gray curve is the real-time binding value curve, and the light gray curve is the fitted average curve. The affinity constants calculated by curve fitting are shown in Table 4.

[0098] Table 4 Affinity-related parameter determination results of rabbit monoclonal antibodies

[0099] Antibody <![CDATA[K off (1 / s)]]> <![CDATA[K on (1 / Ms)]]> <![CDATA[K D (M)]]> 2B10 <![CDATA[3.48×10 -4 ]]> <![CDATA[9.39×10 5 ]]> <![CDATA[3.7×10 -10 ]]> 1F10 <![CDATA[2.26×10 -4 ]]> <![CDATA[2.40×10 5 ]]> <![CDATA[9.4×10 -10 ]]>

[0100] The results showed that the dissociation rate constants of antibodies 2B10 and 1F10 against human intercellular adhesion molecule-1 were 3.48×10 -4 , 2.26×10 -4 ; The binding rate constants were 9.39×10 5 , 2.40×10 5 ; The dissociation equilibrium constant is 3.7×10 -10 , 9.4×10 -10 , showing that the antibody has a high affinity for human intercellular adhesion molecule-1.

[0101] 2) Identification of antigen recognition epitopes: The operation is basically the same as affinity determination, except that the probe is Anti-His / FC Probe. The antigen protein is first immobilized on the probe at a concentration of 10μg / mL. Then, the antibodies to be tested 2B10 / 1F10 are used to bind to the antigen on the probe at a concentration of 3μg / mL. The antigen epitopes recognized by the two antibodies are determined by analyzing their binding to the antigen. The results of antigen determinant cluster recognition of the two antibodies are shown in Figure 4 , where the ordinate represents the change in the thickness of the conjugate after the probe binds to the antibody and protein, and the abscissa represents the binding time of the antibody and antigen protein.

[0102] As can be seen from the figure, antibodies 2B10 and 1F10 recognize different antigenic epitopes of human intercellular adhesion molecule-1 respectively, and the binding sites do not interfere with each other. Therefore, the two can be used as paired antibodies for double antibody sandwich enzyme-linked immunosorbent assay.

[0103] Example 3 Establishment of a double antibody sandwich ELISA based on antibodies 2B10 and 1F10 and its sensitivity test

[0104] Detection antibody - Antibody 1F10 biotin labeling: Prepare antibody 1F10 into a 1 mg / mL solution, and use DMSO to prepare biotin (purchased from Uni-Land, product number: B5064) into a 10 mg / mL solution; take 200 μL of 1 mg / mL antibody 1F10 solution, add 2 μL of 10 mg / mL biotin solution; after mixing, place in a 2-8°C refrigerator to react for 16-20 hours before use.

[0105] The antibody 2B10 was used as the capture antibody and the biotin-labeled antibody 1F10 was used as the detection antibody to establish a double antibody sandwich enzyme-linked immunosorbent assay (ELISA) method, and the steps are as follows: 1) Coating the capture antibody 2B10: dilute the antibody 2B10 with 1×PBS to 2μg / mL, mix it with a vortexer, add it to a 96-well microplate at 100μL / well, cover it with a cover film, and incubate it in a 4°C refrigerator for 16-20h; 2) Washing the plate: after the incubation is completed, discard the liquid in the well, wash the plate once with 1×PBST, add 300μL of the sample, let it stand for 40s, then discard the liquid in the well, and pat the liquid in the well dry on a flat paper; 3) Blocking: Add E013 blocking solution (1×PBS containing 2% BSA, 5% sucrose, 0.05% Tween and 0.1% proclin 300, pH 7.2) was added to the plate at 200 μL / well, covered with a cover film, and blocked at 37°C for 2 h. After blocking, the blocking solution was discarded, the ELISA plate was patted dry, placed in a 37°C oven for 0.5-2 h, and then taken out for use; 4) Add antigen protein: human ICAM-1 protein (purchased from RD, item number ADP4-050) was blocked with E003 blocking solution (1× PBS containing 2% BSA, 0.05% Tween 20, 0.1% proclin 300, pH7.2) for gradient dilution, dilution concentration: 2000, 1000, 500, 250, 125, 62.5, 31.25 and 0pg / mL, then add different concentrations to the ELISA plate at 100μL / well in turn, cover with cover film, and incubate at 37℃ for 2h; 5) Wash the plate: after the incubation is completed, discard the liquid in the well, wash the plate three times with 1×PBST, add 300μL of sample, let it stand for 40s, then discard the liquid in the well, and pat the liquid in the well dry on flat paper; 6) Add detection antibody 1F10: dilute the biotin-labeled antibody 1F10 (B-biotin) to 0.02μg / mL, add 100μL / well to the ELISA plate in turn, cover with cover film, and incubate at 37℃ for 1h; 7) Wash the plate: same as step 5); 8) Add SA-HRP: dilute 100×SA-HRP (horseradish peroxidase labeled streptavidin, purchased from Wuhan Sanying Biotechnology Co., Ltd., catalog number SA00001-0) concentrate 100 times, add 100 μL / well to the ELISA plate, cover with cover film, and incubate at 37°C for 0.5h; 9) Wash the plate: Same as step 5); 10) Add colorimetric solution: add 3,3',5,5'-tetramethylbenzidine (TMB) colorimetric solution (purchased from Tetramethylbenzidine, catalog number 4ATMB1000) to the ELISA plate at 100 μL / well, cover with cover film, and incubate at 37°C for 15min; 11) Read: After the incubation is completed, take out the ELISA plate, add 50 μL of stop solution (1 mol / L hydrochloric acid) to each well, and immediately read with an ELISA reader. With the concentration of human ICAM-1 protein as the horizontal axis, the correction value Y (=OD 450nm-OD 630nm ) as the ordinate, and the standard curve is obtained (see Figure 5 The absorbance value of sensitivity was the sum of the average absorbance value of 16 blank wells (E003 diluent replaced the antibody solution) and 2 times the standard deviation. The concentration obtained by substituting the absorbance value into the standard curve was the sensitivity of the human cell adhesion molecule-1 double antibody sandwich enzyme-linked immunosorbent assay method. The results are shown in Table 5.

[0106] Table 5 Sensitivity test data of double antibody sandwich ELISA based on antibodies 2B10 and 1F10

[0107]

[0108] The above results show that the double antibody sandwich ELISA system established with antibody 2B10 as the capture antibody and antibody 1F10 as the detection antibody was used to detect human intercellular adhesion molecule-1, showing good linearity and a detection sensitivity as low as 5.54 pg / mL, with good sensitivity and accuracy.

[0109] Example 4 Specificity test of double antibody sandwich ELISA system based on antibodies 2B10 and 1F10

[0110] Human Galectin 1 (from Abclonal, Catalog No. RP00007), Human sE-selectin (from Abclonal, Catalog No. RP00293), Human P-selectin (purchased from RD, Catalog No. 841156), Human VCAM-1 (from Abclonal, Catalog No. RP00972), and Mouse VCAM-1 (from Abclonal, Catalog No. RP01176) were used as detection targets, and cross-experiments were conducted with human ICAM-1 (purchased from RD, Catalog No. ADP4-050). Human ICAM-1 protein was diluted to 2000 pg / mL with E003 diluent, and the concentrations of other proteins were 40 ng / mL. The detection method was the same as in Example 3. The results are shown in Table 2. Figure 6 In the figure, H. stands for Human and M. stands for Mouse.

[0111] When the antibody binds to the antigen, a light signal is generated. Figure 6 It was shown that only human ICAM-1 could cause an increase in absorbance value, which indicated that antibodies 2B10 and 1F10 had no obvious cross-reaction to other similar proteins except ICAM-1 protein, proving that the antibodies of the present invention have high specificity for recognizing and binding to human ICAM-1.

[0112] Example 5 Thermal stability test of double antibody sandwich ELISA system based on antibodies 2B10 and 1F10

[0113] The ELISA plate coated with the capture antibody 2B10, the freeze-dried human ICAM-1 protein, and the 100× concentrated detection antibody 1F10 were sealed and stored at -20°C and 37°C for 7 days, respectively, and then taken out and the Y value was tested according to the method of Example 3. The thermal stability of the rabbit monoclonal antibodies 2B10 and 1F10 against human intercellular adhesion molecule-1 was compared based on the standard curve established by comparing the antibody samples treated at different temperatures. The results are shown in Tables 6 and Figure 7 .

[0114] Table 6 Stability test data of double antibody sandwich ELISA based on antibodies 2B10 and 1F10

[0115]

[0116] The results showed that the ELISA plate coated with capture antibody 2B10, biotin-labeled detection antibody or antigen protein destroyed at 37°C for 7 days had CVs of 6.88%, 1.67%, and 3.39% compared with the control group, respectively. The above three components were all destroyed at 37°C for 7 days, and the CV of the control group was 6.88%, which shows that the detection system of the present invention has good stability.

[0117] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An anti-human intercellular adhesion molecule-1 antibody, characterized in that: Selected from the first antibody or the second antibody, wherein: The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the first antibody are shown in SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively; The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the second antibody are shown as SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown as SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, respectively.

2. The anti-human intercellular adhesion molecule-1 antibody according to claim 1, characterized in that The amino acid sequence of the light chain variable region of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; The amino acid sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.

17.

3. The anti-human intercellular adhesion molecule-1 antibody according to claim 2, characterized in that: The amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6; The amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.

16.

4. The anti-human intercellular adhesion molecule-1 antibody according to claim 1, characterized in that The first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; The antigen binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.

5. A nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule or a host cell comprising the nucleic acid molecule, characterized in that: The nucleic acid molecule encodes the first antibody or the second antibody according to any one of claims 1 to 4.

6. The nucleic acid molecule, the recombinant vector comprising the nucleic acid molecule or the host cell comprising the nucleic acid molecule according to claim 5, characterized in that: The nucleotide sequence of the light chain variable region of the first antibody is shown in SEQ ID NO.22, and the nucleotide sequence of the heavy chain variable region is shown in SEQ ID NO.24; The nucleotide sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.26, and the nucleotide sequence of the heavy chain variable region is shown in SEQ ID NO.

28.

7. The nucleic acid molecule, the recombinant vector comprising the nucleic acid molecule or the host cell comprising the nucleic acid molecule according to claim 6, characterized in that: The nucleotide sequence of the light chain of the first antibody is shown in SEQ ID NO.21, and the nucleotide sequence of the heavy chain is shown in SEQ ID NO.23; The nucleotide sequence of the light chain of the second antibody is shown in SEQ ID NO.25, and the nucleotide sequence of the heavy chain is shown in SEQ ID NO.

27.

8. An anti-human intercellular adhesion molecule-1 antibody pair, characterized in that: The method comprises the first antibody and the second antibody as described in any one of claims 1 to 4.

9. Use of the anti-human intercellular adhesion molecule-1 antibody according to any one of claims 1 to 4 or the anti-human intercellular adhesion molecule-1 antibody pair according to claim 8 in the preparation of a human intercellular adhesion molecule-1 detection reagent or kit.

10. A human intercellular adhesion molecule-1 detection reagent or kit, characterized in that: The detection reagent or kit is a double antibody sandwich enzyme-linked immunosorbent assay reagent or kit, comprising the anti-human intercellular adhesion molecule-1 antibody pair as claimed in claim 8, with the first antibody serving as a capture antibody and the second antibody modified with a detection marker serving as a detection antibody.

Citation Information

Patent Citations

  • Anti-human immune globulin G4 monoclonal antibody, preparation method, carrier and kit

    CN117106091A

  • Rabbit monoclonal antibody for resisting human epididymis secretory protein 4 and application of rabbit monoclonal antibody

    CN117487018A